Alta Partners

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Progentos Therapeutics is focused on developing innovative treatments for multiple sclerosis by harnessing the body's natural repair mechanisms. The company creates novel small-molecule therapeutics aimed at activating oligodendrocyte progenitor cells, which are crucial for myelin regeneration. This approach seeks to help patients recover lost functions and enhance their overall quality of life. Through its targeted research and development efforts, Progentos Therapeutics is dedicated to addressing the challenges associated with chronic diseases, particularly in the context of neurological disorders.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Edgewood Oncology is a clinical-stage biotechnology business established to fulfill the potential of BTX-A51 for patients with solid tumors that are genetically specified and hematologic malignancies. Our goal is to create a novel treatment that will prolong and enhance the lives of those with the greatest unmet medical needs.

Harbor Health is a multi-specialty clinic group based in Austin, Texas, founded in 2022. The organization focuses on delivering personalized, patient-centered healthcare by utilizing technology to enhance the patient experience. Harbor Health offers a collaborative approach to healthcare, working closely with individuals to understand their health goals and providing access to specialists when necessary. The clinic provides a variety of services, including primary care, chronic disease management, behavioral health, and overall wellness. Patients benefit from same-day and virtual appointment options, as well as conveniently located clinics, ensuring that healthcare is accessible and responsive to their needs.

Lassen Therapeutics specializes in developing monoclonal antibodies aimed at treating fibrosis, rare diseases, and oncology. The company’s primary candidate, LASN01, targets the IL-11 receptor alpha, a critical component in the IL-6 family of cytokines. IL-11 is a significant mediator of fibrosis and plays an essential role in tumor growth and the organization of the tumor microenvironment. By blocking IL-11's activity, Lassen Therapeutics seeks to provide more effective treatment options compared to traditional approaches that target other factors like TGF-β and CTGF. Through innovative antibody technologies, the company aims to deliver breakthrough therapeutics that improve the lives of patients facing serious health challenges.

MBrace Therapeutics is a privately held biopharmaceutical company focused on enhancing the quality of life for cancer patients through the development of antibody-drug conjugates (ADCs). The company specializes in creating anti-tumor monoclonal human recombinant antibodies that target specific cancer cells. By utilizing advanced technology, MBrace Therapeutics aims to deliver potent toxic drugs directly into cancer cells, allowing for more precise treatment options. This innovative approach is designed to improve therapeutic outcomes and provide healthcare professionals with better tools to combat cancer.

Free Market Health, founded in 2019 and based in Pittsburgh, PA, is a developer of a care-driven marketplace aimed at simplifying the complex specialty medication fulfillment process. The company offers a platform that enhances the efficiency of referral distribution and reimbursement, helping payers and specialty pharmacies navigate the intricacies of the healthcare landscape. By focusing on value drivers and accountabilities for patient referrals, Free Market Health enables timely access to lifesaving and life-altering medications. The company prioritizes the needs of all stakeholders, particularly patients, by optimizing resources and maximizing opportunities within the healthcare system.

BetterVet is a veterinary startup founded in 2020 and based in Boston, Massachusetts. The company offers an online platform that enhances the veterinary healthcare experience by providing home visits and telehealth services. Pet owners can easily schedule virtual video consultations and arrange for in-home veterinary exams through the company's app. By focusing on mobile veterinary services, BetterVet aims to deliver convenient and accessible care for pets in the comfort of their homes.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

Everside Health is a direct primary care provider founded in 2010 and based in Denver, Colorado. The company offers a range of services, including biometric screenings, health risk assessments, lifestyle coaching, and acute care, catering to patients across the nation. Everside's healthcare delivery model is data-driven and patient-centric, focusing on convenient on-site, near-site, and virtual care options. By aligning incentives among patients, physicians, and benefit providers, Everside aims to enhance patient engagement and overall health while simultaneously reducing the total cost of care.

DEM BioPharma is an immuno-oncology company focused on developing innovative therapies aimed at eradicating cancer by targeting the innate immune system. The company has created a platform that specializes in the next generation of macrophage immunotherapies, which work by activating macrophages and immune phagocytes to effectively eliminate tumors. By researching and harnessing these immune responses, DEM BioPharma aims to provide healthcare researchers with advanced treatments that specifically target signals on both cancer cells and macrophages, offering new hope in the fight against cancer.

Kelonia Therapeutics is developing a new wave of genetic medicines using its next-generation vivo gene delivery platform. The company's cutting-edge in vivo gene delivery technology is simple and elegant, relying on a few potent lentiviral vector-like particles to precisely and efficiently deliver genetic cargo to the desired target tissue, and only that tissue, every time. To deliver genetic cargo only to the desired tissue, the lentiviral vector gene delivery platform employs a simple and elegant solution based on decades of research, development, and technical experience. Kelonia's mission is to develop a new wave of accessible genetic medicines that will transform the lives of patients suffering from a broad range of conditions.

Free Market Health, founded in 2019 and based in Pittsburgh, PA, is a developer of a care-driven marketplace aimed at simplifying the complex specialty medication fulfillment process. The company offers a platform that enhances the efficiency of referral distribution and reimbursement, helping payers and specialty pharmacies navigate the intricacies of the healthcare landscape. By focusing on value drivers and accountabilities for patient referrals, Free Market Health enables timely access to lifesaving and life-altering medications. The company prioritizes the needs of all stakeholders, particularly patients, by optimizing resources and maximizing opportunities within the healthcare system.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, that specializes in developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in cancer therapies through its proprietary SNÅP platform, which facilitates rapid and precise drug design by generating iterative molecular snapshots. Tyra is particularly focused on creating selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family, which are implicated in approximately 7% of all cancers. The company's lead product candidate, TYRA-300, specifically targets FGFR3 and is initially aimed at patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through its innovative approach, Tyra Biosciences seeks to improve treatment outcomes for cancer patients by providing alternatives to existing therapies.

DispatchHealth Management, LLC is a provider of on-demand mobile and virtual healthcare services, founded in 2013 and headquartered in Denver, Colorado. The company offers a wide range of services, including evaluation and treatment for acute injuries and illnesses, laceration repair, splinting of injured extremities, and management of conditions like nosebleeds and catheter placements. It also facilitates medication administration, laboratory testing, outpatient imaging arrangements, and coordination with primary care physicians and home health agencies. By delivering care directly to patients in their homes or workplaces, DispatchHealth aims to enhance the capabilities of existing care teams while providing high-quality, cost-effective healthcare solutions.

PatientsLikeMe, Inc. operates a healthcare data-sharing platform that facilitates the exchange of symptoms, treatments, health data, and personal experiences among patients, caregivers, healthcare professionals, and researchers. Founded in 2004 and based in Cambridge, Massachusetts, the platform serves over 600,000 members and focuses on a broad range of health conditions, including cancer, mental health, and chronic diseases. PatientsLikeMe enables users to discover new treatment options, connect with peers, and engage in health management to enhance their outcomes. The company collaborates with major pharmaceutical firms and government organizations to incorporate patient insights into research, development, and public policy. Additionally, PatientsLikeMe has published over 100 research studies, establishing itself as a credible resource for real-world disease information. It is a subsidiary of United Healthcare Services, Inc.

MBrace Therapeutics is a privately held biopharmaceutical company focused on enhancing the quality of life for cancer patients through the development of antibody-drug conjugates (ADCs). The company specializes in creating anti-tumor monoclonal human recombinant antibodies that target specific cancer cells. By utilizing advanced technology, MBrace Therapeutics aims to deliver potent toxic drugs directly into cancer cells, allowing for more precise treatment options. This innovative approach is designed to improve therapeutic outcomes and provide healthcare professionals with better tools to combat cancer.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

DispatchHealth Management, LLC is a provider of on-demand mobile and virtual healthcare services, founded in 2013 and headquartered in Denver, Colorado. The company offers a wide range of services, including evaluation and treatment for acute injuries and illnesses, laceration repair, splinting of injured extremities, and management of conditions like nosebleeds and catheter placements. It also facilitates medication administration, laboratory testing, outpatient imaging arrangements, and coordination with primary care physicians and home health agencies. By delivering care directly to patients in their homes or workplaces, DispatchHealth aims to enhance the capabilities of existing care teams while providing high-quality, cost-effective healthcare solutions.

Lassen Therapeutics specializes in developing monoclonal antibodies aimed at treating fibrosis, rare diseases, and oncology. The company’s primary candidate, LASN01, targets the IL-11 receptor alpha, a critical component in the IL-6 family of cytokines. IL-11 is a significant mediator of fibrosis and plays an essential role in tumor growth and the organization of the tumor microenvironment. By blocking IL-11's activity, Lassen Therapeutics seeks to provide more effective treatment options compared to traditional approaches that target other factors like TGF-β and CTGF. Through innovative antibody technologies, the company aims to deliver breakthrough therapeutics that improve the lives of patients facing serious health challenges.

Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California, that specializes in developing small molecule therapies for cancer treatment. Founded in 2018, the company aims to address drug resistance in cancer therapies through its proprietary SNÅP platform, which facilitates rapid and precise drug design by generating iterative molecular snapshots. Tyra is particularly focused on creating selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family, which are implicated in approximately 7% of all cancers. The company's lead product candidate, TYRA-300, specifically targets FGFR3 and is initially aimed at patients with metastatic urothelial carcinoma of the bladder and urinary tract. Through its innovative approach, Tyra Biosciences seeks to improve treatment outcomes for cancer patients by providing alternatives to existing therapies.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Variant Bio Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutics through the study of human genetic diversity. Founded in 2018, the company identifies individuals and populations that exhibit extreme traits of medical significance, utilizing advanced sequencing technologies and analytic methods to uncover the genes and pathways associated with these traits. By leveraging insights from genetic research, Variant Bio aims to discover new therapeutic targets for conditions such as neurodegenerative, autoimmune, and cardiometabolic diseases. The company's innovative approach combines statistical genetics and machine learning, enhancing the potential for genomic drug discovery to address unmet medical needs.

DispatchHealth Management, LLC is a provider of on-demand mobile and virtual healthcare services, founded in 2013 and headquartered in Denver, Colorado. The company offers a wide range of services, including evaluation and treatment for acute injuries and illnesses, laceration repair, splinting of injured extremities, and management of conditions like nosebleeds and catheter placements. It also facilitates medication administration, laboratory testing, outpatient imaging arrangements, and coordination with primary care physicians and home health agencies. By delivering care directly to patients in their homes or workplaces, DispatchHealth aims to enhance the capabilities of existing care teams while providing high-quality, cost-effective healthcare solutions.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.

Everside Health is a direct primary care provider founded in 2010 and based in Denver, Colorado. The company offers a range of services, including biometric screenings, health risk assessments, lifestyle coaching, and acute care, catering to patients across the nation. Everside's healthcare delivery model is data-driven and patient-centric, focusing on convenient on-site, near-site, and virtual care options. By aligning incentives among patients, physicians, and benefit providers, Everside aims to enhance patient engagement and overall health while simultaneously reducing the total cost of care.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on xenotransplantation. The company aims to address the critical shortage of organ donors by utilizing advanced gene editing techniques to develop safe and effective cells, tissues, and organs for human transplantation. Their mission is to eliminate the waiting period associated with organ transplants, providing patients with access to life-saving organs. By harnessing cutting-edge genetic editing technology, Qihan Biotech seeks to create viable organs that can be transplanted into humans, thereby contributing to a solution for the global organ donor crisis.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

DispatchHealth Management, LLC is a provider of on-demand mobile and virtual healthcare services, founded in 2013 and headquartered in Denver, Colorado. The company offers a wide range of services, including evaluation and treatment for acute injuries and illnesses, laceration repair, splinting of injured extremities, and management of conditions like nosebleeds and catheter placements. It also facilitates medication administration, laboratory testing, outpatient imaging arrangements, and coordination with primary care physicians and home health agencies. By delivering care directly to patients in their homes or workplaces, DispatchHealth aims to enhance the capabilities of existing care teams while providing high-quality, cost-effective healthcare solutions.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

GenePeeks, Inc. is a genetic information company headquartered in New York, New York, that focuses on reducing the risk of heritable diseases through innovative technology. Incorporated in 2009, the company has developed a proprietary software platform that digitally combines the DNA of prospective parents to simulate genetic recombination and reduction. This process generates a comprehensive analysis of potential future children’s genetic profiles, identifying disease risks that existing pre-conception screening methods may overlook. By utilizing Next-Gen sequencing data, GenePeeks creates tens of thousands of virtual genomes, enabling healthcare providers to assess high-risk genetic matches and enhance their understanding of clinically relevant genotypes and variants. The company's mission is to help families safeguard the health of future generations by providing deeper genetic insights.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

St. George's University, established in 1976 in Saint George's, Grenada, is a prominent educational institution that offers a wide range of graduate and undergraduate programs in medicine, veterinary medicine, public health, arts, and sciences. Attracting students and faculty from over 140 countries, the university provides a multicultural environment on its True Blue campus, equipped with state-of-the-art facilities. With more than 14,000 graduates, St. George's University has significantly contributed to the global workforce in healthcare and other fields. The university’s programs are recognized by various governing authorities and are affiliated with numerous educational institutions in the United States, United Kingdom, Canada, Australia, and Ireland. Beyond education, St. George's University plays a vital role in the Grenadian economy, contributing over $100 million annually through employment, local services, and community outreach initiatives. The institution also invests in public health and social services, supporting various charities and enhancing local healthcare systems. Additionally, since 2005, it has provided over $70 million in scholarships to students from the Caribbean, fostering opportunities in medicine and related fields.

Virobay Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on developing and commercializing novel therapies for various medical conditions, including neuropathic pain, autoimmune diseases, liver fibrosis, cancer, and Alzheimer's disease. The company's pipeline includes VBY-129, a cathepsin S inhibitor aimed at treating neuropathic pain and Crohn's disease, and VBY-376, an orally-administered cathepsin B inhibitor for liver fibrosis associated with nonalcoholic steatohepatitis. Additionally, VBY-825 is designed to inhibit multiple cathepsins to mitigate autoimmune attacks on bile ducts and reverse fibrosis. Virobay has also licensed VBY-891 to LEO Pharma A/S for specific dermatological uses, such as psoriasis. Founded in 2006, Virobay is dedicated to addressing significant unmet medical needs through its cysteine cathepsin platform, which focuses on developing safer and more effective treatments by regulating essential cellular processes.

Lumena Pharmaceuticals is focused on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target intestinal transporters, minimizing systemic toxicity and absorption in the body. Their lead candidate, LUM001, has undergone extensive evaluation through 12 clinical studies involving over 1,400 subjects, positioning it for rapid advancement in treating cholestatic liver disease in both pediatric and adult patients. In addition to its primary goal of addressing rare liver diseases, Lumena's innovative therapeutic approach shows promise for treating metabolic liver diseases, a significant and rising health concern affecting both children and adults.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

Neothetics, Inc. was a clinical-stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. Founded in 2007 and based in San Diego, California, the company aimed to address cosmetic concerns through innovative treatments. Its primary product candidate, LIPO-202, was an injectable formulation designed to reduce localized fat deposits, specifically targeting submental fat under the chin and central abdominal bulging in non-obese individuals. In January 2018, Neothetics was acquired by Evofem Biosciences in a reverse merger transaction, marking a significant shift in its business trajectory. The company was previously known as Lipothera, Inc. before rebranding in August 2014.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, dedicated to developing treatments for complex rare diseases. Its primary focus is on Friedreich's ataxia, a rare and progressive genetic disorder, for which it is advancing its lead compound, CTI-1601, through a Phase 1 clinical program. CTI-1601 is designed as a recombinant fusion protein that delivers human frataxin, an essential protein, directly to the mitochondria using a novel cell-penetrating peptide technology. In addition to Friedreich's ataxia, Larimar aims to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases associated with deficiencies in bioactive compounds.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.

Kite Pharma is a clinical-stage biotechnology company focused on developing innovative immune-based therapies for various cancer indications. The company is dedicated to designing and advancing proprietary product candidates that leverage the patient's immune system to combat tumor cells. By harnessing the potential of cell therapy, Kite Pharma aims to provide effective treatment options and improve the management of a wide range of cancer types, offering new strategies in the fight against this disease.

Lumena Pharmaceuticals is focused on developing oral therapeutics for rare liver diseases, aiming to enhance liver function and alleviate disease symptoms. The company's clinical-stage product candidates are designed to selectively target intestinal transporters, minimizing systemic toxicity and absorption in the body. Their lead candidate, LUM001, has undergone extensive evaluation through 12 clinical studies involving over 1,400 subjects, positioning it for rapid advancement in treating cholestatic liver disease in both pediatric and adult patients. In addition to its primary goal of addressing rare liver diseases, Lumena's innovative therapeutic approach shows promise for treating metabolic liver diseases, a significant and rising health concern affecting both children and adults.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Carbylan Therapeutics, founded in 2004 and headquartered in Palo Alto, California, is a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing proprietary combination therapies. The company's primary focus is on addressing pain associated with osteoarthritis of the knee, utilizing innovative approaches that include polysaccharides, biopolymers, and related pharmaceutical products. Carbylan Therapeutics aims to deliver effective therapies to meet significant unmet clinical needs in large and growing markets.

Neothetics, Inc. was a clinical-stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. Founded in 2007 and based in San Diego, California, the company aimed to address cosmetic concerns through innovative treatments. Its primary product candidate, LIPO-202, was an injectable formulation designed to reduce localized fat deposits, specifically targeting submental fat under the chin and central abdominal bulging in non-obese individuals. In January 2018, Neothetics was acquired by Evofem Biosciences in a reverse merger transaction, marking a significant shift in its business trajectory. The company was previously known as Lipothera, Inc. before rebranding in August 2014.

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, dedicated to developing treatments for complex rare diseases. Its primary focus is on Friedreich's ataxia, a rare and progressive genetic disorder, for which it is advancing its lead compound, CTI-1601, through a Phase 1 clinical program. CTI-1601 is designed as a recombinant fusion protein that delivers human frataxin, an essential protein, directly to the mitochondria using a novel cell-penetrating peptide technology. In addition to Friedreich's ataxia, Larimar aims to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases associated with deficiencies in bioactive compounds.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

SARcode Bioscience is a private biopharmaceutical company based in San Francisco that focuses on developing a novel class of small molecule antagonists targeting lymphocyte function-associated antigen-1 (LFA-1). These antagonists are being developed as topical agents aimed at addressing significant unmet medical needs in the fields of ophthalmology, dermatology, and other inflammatory diseases. By targeting LFA-1, SARcode aims to create innovative treatments that can improve patient outcomes in these areas.

Aerie Pharmaceuticals is a biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases. Founded in 2005, the company has its headquarters in Bridgewater, New Jersey, and research facilities in Research Triangle Park, North Carolina. Aerie's portfolio includes Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for similar indications; AVX-012, a clinical-stage product candidate for dry eye; and AR-1105 and AR-13503 sustained-release implants for retinal diseases. The company collaborates with DSM on research, development, and licensing agreements.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Vertiflex Inc. is a medical device company based in Carlsbad, California, specializing in minimally invasive solutions for lumbar spinal stenosis (LSS). Founded in 2005, the company develops advanced spinal surgery technologies, including the Superion Interspinous Spacer, a titanium implant designed to provide motion preservation and indirect decompression for patients with moderate lumbar spinal stenosis. Additionally, Vertiflex offers the Totalis Direct Decompression System, which includes specialized instruments for performing minimally invasive direct decompression of the lumbar spine. By focusing on procedures that minimize tissue trauma, Vertiflex aims to bridge the gap between conservative care and traditional spine surgery, enhancing treatment options for patients suffering from lumbar stenosis. As of June 2019, Vertiflex operates as a subsidiary of Boston Scientific Corporation.

PneumRx, Inc. is a medical device company founded in 2004 and based in Mountain View, California. The company specializes in developing minimally invasive treatments specifically for patients suffering from emphysema. Its primary product is the RePneu Lung Volume Reduction Coil, an investigational device designed to improve lung function and quality of life for individuals affected by this chronic respiratory condition.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.

Pathwork Diagnostics, located in Redwood City, California, specializes in developing and delivering innovative molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers, by utilizing genomic information from the tumors. Pathwork Diagnostics offers laboratory services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen tissues, providing essential support in cancer diagnosis and treatment planning.

Taligen Therapeutics is dedicated to discovering and developing innovative protein therapeutics aimed at modulating the alternative pathway of the complement system. This approach targets a range of inflammatory conditions and diseases. The company's primary therapeutic candidates include monoclonal antibodies and recombinant fusion proteins designed to address key factors in the alternative pathway, which has been identified as a significant mechanism in the inflammatory response. By focusing on the regulation of the complement system, Taligen Therapeutics seeks to create effective treatments for various inflammatory and immune diseases.

Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Stamford, Connecticut, specializing in the development and commercialization of innovative therapeutics for pain and pruritus. The company primarily focuses on its lead product candidate, CR845 (difelikefalin), which is designed to selectively target kappa opioid receptors and is currently undergoing Phase III clinical trials for treating moderate-to-severe chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Cara is also advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is in trials for pruritus associated with chronic liver disease and atopic dermatitis. Furthermore, the company is developing CR845/difelikefalin Injection for acute postoperative pain, having completed Phase II/III trials. Cara Therapeutics collaborates with Maruishi Pharmaceutical Co., Ltd. and Chong Kun Dang Pharmaceutical Corporation for the development and commercialization of its product candidates in Japan and South Korea, respectively. Founded in 2004, Cara Therapeutics aims to leverage its proprietary drug screening technology to create a pipeline of first-in-class therapeutics.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.

Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Virobay Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on developing and commercializing novel therapies for various medical conditions, including neuropathic pain, autoimmune diseases, liver fibrosis, cancer, and Alzheimer's disease. The company's pipeline includes VBY-129, a cathepsin S inhibitor aimed at treating neuropathic pain and Crohn's disease, and VBY-376, an orally-administered cathepsin B inhibitor for liver fibrosis associated with nonalcoholic steatohepatitis. Additionally, VBY-825 is designed to inhibit multiple cathepsins to mitigate autoimmune attacks on bile ducts and reverse fibrosis. Virobay has also licensed VBY-891 to LEO Pharma A/S for specific dermatological uses, such as psoriasis. Founded in 2006, Virobay is dedicated to addressing significant unmet medical needs through its cysteine cathepsin platform, which focuses on developing safer and more effective treatments by regulating essential cellular processes.

FoldRx Pharmaceuticals, Inc. is focused on the discovery and development of disease-modifying drug therapies targeting diseases associated with protein misfolding and amyloidosis. Established in 2003 and based in Cambridge, Massachusetts, the company has advanced clinical programs aimed at treating genetic neurologic and cardiovascular disorders, specifically transthyretin-associated amyloidoses involving polyneuropathy and cardiomyopathy. Additionally, FoldRx is engaged in research programs addressing conditions such as Parkinson's disease and cystic fibrosis. By developing therapies that address the accumulation of misfolded proteins, the company aims to enhance treatment options for healthcare professionals dealing with these complex disorders.

Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

TransMedics Group Inc is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage organ failure. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system designed to overcome the limitations of traditional cold storage methods for organ preservation. By replicating near-physiologic conditions for donor organs outside the human body, the OCS enhances the viability and functionality of organs prior to transplantation, thereby improving clinical outcomes. TransMedics aims to increase heart and lung transplant volumes while reducing learning curves for healthcare providers, ultimately addressing critical needs in organ transplantation.

Virobay Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on developing and commercializing novel therapies for various medical conditions, including neuropathic pain, autoimmune diseases, liver fibrosis, cancer, and Alzheimer's disease. The company's pipeline includes VBY-129, a cathepsin S inhibitor aimed at treating neuropathic pain and Crohn's disease, and VBY-376, an orally-administered cathepsin B inhibitor for liver fibrosis associated with nonalcoholic steatohepatitis. Additionally, VBY-825 is designed to inhibit multiple cathepsins to mitigate autoimmune attacks on bile ducts and reverse fibrosis. Virobay has also licensed VBY-891 to LEO Pharma A/S for specific dermatological uses, such as psoriasis. Founded in 2006, Virobay is dedicated to addressing significant unmet medical needs through its cysteine cathepsin platform, which focuses on developing safer and more effective treatments by regulating essential cellular processes.

Coapt Systems, Inc. specializes in the design, development, and manufacturing of bio-absorbable implants intended for soft tissue fixation in facial cosmetic surgery. Its product offerings include various fixation devices such as the ENDOTINE Forehead 3.0 and ENDOTINE Midface ST 4.5, which are employed in procedures like forehead lifts, brow lifts, and midface suspensions. The company also provides surgical instruments and tools, including insertion kits and manual drills, to facilitate the use of its implants. Coapt Systems aims to support surgeons in achieving effective and secure tissue fixation during surgical procedures, enhancing outcomes for patients undergoing cosmetic interventions.

Corcept Therapeutics Incorporated is a pharmaceutical company focused on discovering, developing, and commercializing treatments for severe metabolic, oncologic, and psychiatric disorders. Headquartered in Menlo Park, California, the company is known for its product Korlym, a once-daily oral medication using mifepristone to address hyperglycemia caused by hypercortisolism in adults with endogenous Cushing’s syndrome, particularly those with type 2 diabetes or glucose intolerance who are not surgical candidates. In addition to Korlym, Corcept is advancing several clinical trials, including relacorilant, which is in Phase III for Cushing’s syndrome, and a combination therapy of Abraxane and relacorilant for serous ovarian tumors. The company is also exploring a selective cortisol modulator for metastatic castration-resistant prostate cancer and another for antipsychotic-induced weight gain. Founded in 1998, Corcept Therapeutics continues to prioritize the modulation of cortisol's effects, which are crucial given the hormone's widespread impact on various bodily tissues.

aTyr Pharma is a biotherapeutics company based in San Diego, California, specializing in the discovery and development of innovative medicines utilizing novel immunological pathways. The company focuses primarily on ATYR1923, a clinical-stage fusion protein designed to down-regulate immune engagement in interstitial lung diseases by binding to the neuropilin-2 receptor. This candidate is currently undergoing Phase 1b/2a clinical trials. aTyr Pharma has established a strong intellectual property portfolio centered around Physiocrine-based compositions and therapeutic applications, particularly in immunomodulation disorders related to inflammation and immunity. Additionally, the company has formed collaborations with several institutions, including the University of Nebraska Medical Center, CSL Behring, Boston Children’s Hospital, and the Medical University of South Carolina, to advance its research and development efforts. Founded in 2005 by a prominent scientist from The Scripps Research Institute, aTyr is supported by leading life sciences investors.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.

Neothetics, Inc. was a clinical-stage specialty pharmaceutical company focused on developing therapeutics for the aesthetic market. Founded in 2007 and based in San Diego, California, the company aimed to address cosmetic concerns through innovative treatments. Its primary product candidate, LIPO-202, was an injectable formulation designed to reduce localized fat deposits, specifically targeting submental fat under the chin and central abdominal bulging in non-obese individuals. In January 2018, Neothetics was acquired by Evofem Biosciences in a reverse merger transaction, marking a significant shift in its business trajectory. The company was previously known as Lipothera, Inc. before rebranding in August 2014.

Avid Radiopharmaceuticals is a biopharmaceutical company based in Philadelphia, PA, focused on developing molecular imaging agents designed to improve the medical management of chronic diseases. The company aims to create innovative imaging compounds that can detect and monitor the early stages of pathological changes, facilitating earlier diagnoses and enhancing the management of treatment options. One of their key products, Amyvid, serves as an imaging tool for positron emission tomography, specifically targeting the detection of beta-amyloid plaques in the brain, which is crucial for understanding conditions like Alzheimer's disease. Avid's mission underscores their commitment to transforming disease management through advanced imaging technologies.

Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing targeted inhibitors for treating various cancers, both hematologic and solid. Its lead candidate, vecabrutinib, is a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor currently undergoing Phase 1b/2 clinical trials for chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also advancing SNS-510, which is in preclinical studies for solid tumors and hematologic malignancies. Additionally, Sunesis is involved in partnered programs, including TAK-580, a pan-Raf inhibitor in Phase 1 trials for pediatric low-grade glioma, and vosaroxin, an anti-cancer agent that affects DNA and inhibits topoisomerase II. Collaborative efforts with Biogen Idec and Takeda Pharmaceutical focus on developing small molecule BTK inhibitors and preclinical PDK1 inhibitors, respectively. Founded in 1998, Sunesis Pharmaceuticals is headquartered in South San Francisco, California.

Sutro Biopharma is a clinical-stage drug discovery, development, and manufacturing company based in South San Francisco, California. The company specializes in creating next-generation protein therapeutics aimed at treating cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Among its product candidates are STRO-001, an antibody-drug conjugate targeting CD74 for patients with multiple myeloma and non-Hodgkin lymphoma, and STRO-002, which is directed against folate receptor-alpha for individuals with ovarian and endometrial cancers. Sutro Biopharma also has a collaboration and licensing agreement with Celgene Corporation to develop bispecific antibodies and antibody-drug conjugates primarily in the field of immuno-oncology. Founded in 2003, the company continues to advance its innovative therapeutic candidates through rigorous clinical development.

Aegis is a privately held company that builds solutions for embedded monitoring of advanced optical networks. The company's Active Thin Films are manufactured using proven high-volume processes with demonstrated high yield and superb uniformity. Aegis's solutions benefit from the reliability of solid-state, silicon-based design, extreme scalability, and low-cost packaging architectures.

7TM Pharma is a biotech company based in Lyngby, Hovedstaden, specializing in the discovery and development of therapeutic drugs targeting diabetes, gastrointestinal disorders, metabolic conditions, asthma, and vascular diseases. Founded in 2000, the company has developed a portfolio of innovative treatments, including TM38837, a small molecule CB1 receptor antagonist, and TM30339, a selective agonist for the NPY Y4 receptor, aimed at addressing gastrointestinal disorders and short bowel syndrome. Additionally, 7TM Pharma is advancing a CRTH2 antagonist, an oral medication intended for the treatment of inflammatory and respiratory diseases. Through its focus on areas with significant unmet medical needs, the company seeks to provide effective solutions for clinically obese patients and others suffering from these conditions.

Intradigm is a private biotechnology company focused on developing systematic RNA interference (RNAi) therapeutics aimed at treating serious diseases, with an initial emphasis on oncology. The company leverages its expertise in drug development and delivery to create a proprietary RNAi platform, which includes unique RNAi Nanoplex delivery technology. This technology enables the targeted delivery of RNAi therapeutics to specific tissues through systemic administration. Intradigm's portfolio encompasses RNAi molecules, biodegradable polycationic polymers for therapeutic delivery, and a range of siRNA sequences targeting various oncology and other disease-related applications.